Dr. Matthew Harmelink, MD
Claim this profileChildren's Wisconsin
Studies Duchenne Muscular Dystrophy
Studies Muscular Dystrophy
4 reported clinical trials
5 drugs studied
Area of expertise
1Duchenne Muscular Dystrophy
DMD negative
DMD positive
2Muscular Dystrophy
DMD negative
DMD positive
Affiliated Hospitals
Clinical Trials Matthew Harmelink, MD is currently running
Gene Therapy
for Duchenne Muscular Dystrophy
The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 weeks. All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.
Recruiting1 award Phase 35 criteria
Cell Therapy
for Duchenne Muscular Dystrophy
This trial tests a cell therapy called CAP-1002 in boys and young men with Duchenne muscular dystrophy. The therapy involves giving special cells through an IV to help improve muscle function. The goal is to see if this treatment can repair or regenerate damaged muscles.
Recruiting1 award Phase 31 criteria
More about Matthew Harmelink, MD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Matthew Harmelink, MD has experience with
- Placebo
- SRP-9001 (Delandistrogene Moxeparvovec)
- Zolgensma
- Prospective Observational Registry
- CAP-1002
Breakdown of trials Matthew Harmelink, MD has run
Duchenne Muscular Dystrophy
Muscular Dystrophy
Spinal Muscular Atrophy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Harmelink, MD specialize in?
Matthew Harmelink, MD focuses on Duchenne Muscular Dystrophy and Muscular Dystrophy. In particular, much of their work with Duchenne Muscular Dystrophy has involved DMD negative patients, or patients who are DMD positive.
Is Matthew Harmelink, MD currently recruiting for clinical trials?
Yes, Matthew Harmelink, MD is currently recruiting for 2 clinical trials in Milwaukee Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Matthew Harmelink, MD has studied deeply?
Yes, Matthew Harmelink, MD has studied treatments such as Placebo, SRP-9001 (Delandistrogene Moxeparvovec), Zolgensma.
What is the best way to schedule an appointment with Matthew Harmelink, MD?
Apply for one of the trials that Matthew Harmelink, MD is conducting.
What is the office address of Matthew Harmelink, MD?
The office of Matthew Harmelink, MD is located at: Children's Wisconsin, Milwaukee, Wisconsin 53226 United States. This is the address for their practice at the Children's Wisconsin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.